Jilin Aodong Pharmaceutical Group Co., Ltd. (SHE:000623)

SHE:000623 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,268	2,537	3,404	2,850	2,263	2,237
Other Revenue	73.86	73.86	45.58	17.95	41.05	15.11
Revenue	2,341	2,611	3,449	2,868	2,304	2,252
Revenue Growth (YoY)	-22.08%	-24.31%	20.25%	24.50%	2.31%	-27.09%
Cost of Revenue	439.88	1,602	1,768	1,417	1,111	929.01
Gross Profit	1,902	1,008	1,681	1,451	1,193	1,323
Selling, General & Admin	351.42	1,055	1,354	1,181	1,093	1,279
Research & Development	26.39	82.2	124.98	85.68	49.42	67.21
Other Operating Expenses	-615.89	37.28	46.43	42.77	39.3	43.02
Operating Expenses	-255.31	1,169	1,546	1,321	1,187	1,388
Operating Income	2,157	-160.4	134.53	129.91	5.87	-65.74
Interest Expense	-15	-92.08	-144.35	-142.99	-130.49	-126.82
Interest & Investment Income	546.25	1,877	1,382	1,697	2,070	1,916
Other Non Operating Income (Expenses)	-40.12	7.42	107.65	589.79	-7.62	-5.28
EBT Excluding Unusual Items	2,648	1,632	1,479	2,274	1,937	1,718
Impairment of Goodwill	-	-	-	-	-	-24.28
Gain (Loss) on Sale of Investments	-98.44	-121.67	-111.06	-632.66	-259.53	-75.98
Gain (Loss) on Sale of Assets	-0.2	-0.67	36.16	3.16	-0.94	-0.64
Asset Writedown	-65.33	-65.33	-3.25	-1.25	-2.84	-1.25
Other Unusual Items	127.57	77.54	98.83	77.92	92.6	100.79
Pretax Income	2,612	1,521	1,500	1,721	1,767	1,717
Income Tax Expense	55.56	2.23	55.83	-80.16	-4.19	25.14
Earnings From Continuing Operations	2,556	1,519	1,444	1,801	1,771	1,691
Minority Interest in Earnings	11.8	32.2	15.54	-20.2	9.64	17.46
Net Income	2,568	1,551	1,460	1,781	1,781	1,709
Net Income to Common	2,568	1,551	1,460	1,781	1,781	1,709
Net Income Growth	79.60%	6.27%	-18.02%	0.02%	4.19%	21.75%
Shares Outstanding (Basic)	1,178	1,177	1,125	1,135	1,139	1,158
Shares Outstanding (Diluted)	1,178	1,177	1,295	1,301	1,259	1,276
Shares Change (YoY)	-7.34%	-9.08%	-0.46%	3.36%	-1.39%	-0.28%
EPS (Basic)	2.18	1.32	1.30	1.57	1.56	1.48
EPS (Diluted)	2.18	1.32	1.23	1.47	1.51	1.43
EPS Growth	77.78%	7.39%	-16.35%	-2.93%	5.70%	20.92%
Free Cash Flow	-	-214.5	-351.46	152.89	11.54	163.02
Free Cash Flow Per Share	-	-0.18	-0.27	0.12	0.01	0.13
Dividend Per Share	0.500	0.500	0.600	0.300	0.300	0.200
Dividend Growth	-37.50%	-16.67%	100.00%	-	50.00%	-
Gross Margin	81.21%	38.62%	48.74%	50.59%	51.76%	58.74%
Operating Margin	92.12%	-6.14%	3.90%	4.53%	0.26%	-2.92%
Profit Margin	109.67%	59.43%	42.33%	62.09%	77.29%	75.89%
Free Cash Flow Margin	-	-8.22%	-10.19%	5.33%	0.50%	7.24%
EBITDA	2,363	45.48	339.83	326.49	200.39	129.73
EBITDA Margin	100.93%	1.74%	9.85%	11.38%	8.70%	5.76%
D&A For EBITDA	206.31	205.88	205.3	196.58	194.53	195.46
EBIT	2,157	-160.4	134.53	129.91	5.87	-65.74
EBIT Margin	92.12%	-6.14%	3.90%	4.53%	0.26%	-2.92%
Effective Tax Rate	2.13%	0.15%	3.72%	-	-	1.47%
Revenue as Reported	701.07	2,611	3,449	2,868	2,304	2,252
Advertising Expenses	-	183.98	277.99	202.59	160.73	212.53

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.